Renal and haemodynamic responses to a novel kappa opioid receptor agonist, niravoline (RU 51,599), in rats with cirrhosis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 11, Issue 9, 1996, Pages 857-863

  Moreau, Richard ^a   Cailmail, Stephane ^a   Hamon, Gilles ^b   Lebrec, Didier ^a  

^a BEAUJON HOSPITAL   (France)

^b SANOFI   (France)

Author keywords

Niravoline; Opioid agonist; Portal hypertension; Water metabolism

Indexed keywords

NIRAVOLINE; OPIATE AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; LIVER CIRRHOSIS; NONHUMAN; PORTAL HYPERTENSION; PRIORITY JOURNAL; RAT;

EID: 0029799582     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1996.tb00093.x     Document Type: Article

References (24)

1. Linas SL, Anderson RJ, Guggenheim SJ, Robertson GL, Berl T. Role of vasopressin in impaired water excretion in conscious rats with experimental cirrhosis. Kidney Int. 1981; 20: 173-80.
2. Bichet DG, Szatalowicz V, Chaimovitz C, Schrier RW. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann. Intern. Med. 1982; 96: 413-17.
3. Bichet DG, Van Putten VJ, Schrier RW. Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis. N. Engl. J. Med. 1982; 307: 1552-7.
4. Camps J, Sola J, Arroyo V et al. Temporal relationship between the impairment of free water excretion and antidiuretic hormone hypersecretion in rats with experimental cirrhosis. Gastroenterology 1987; 93: 498-505.
5. Claria J, Jimenez W, Arroyo V et al. Blockade of the hydro-osmotic effect of vasopressin normalizes water excretion in cirrhotic rats. Gastroenterology 1989; 97: 1294-9.
6. Tsuboi Y, Ishikawa G, Okada K, Saito T. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int. 1994; 46: 237-44.
7. Kim JK, Summer SN, Howard RL, Schrier RW. Vasopressin gene expression in rats with experimental cirrhosis. Hepatology 1993; 17: 143-7.
8. Arroyo V, Claria J, Salo J, Jimenez W. Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Semin. Liver Dis. 1994; 14: 44-58.
9. Salerno F, Delbo A, Maggi A et al. Vasopressin release and water metabolism in patients with cirrhosis. J. Hepatol. 1994; 21: 822-30
10. Asahina Y, Izumi N, Enomoto N et al. Increased gene expression of water channel in cirrhotic rat kidneys. Hepatology 1995; 21: 169-73.
11. Ohnishi A, Mihara M, Yasuda S, Tomono Y, Hasegawa J, Tanaka T. Aquaretic effect of the stable dynorphin-A analog E2078 in the human. J. Pharmacol. Exp. Ther. 1994; 270: 342-7.
12. Wang Y, Clarke GD, Sbacchi M, Petrone G, Brooks DP. Contribution of alpha-2 adrenoceptors to kappa opioid agonist-induced water diuresis in the rat. J. Pharmacol. Exp. Ther. 1994; 270: 244-9.
13. Sinnassamy P, Sultan E, Bichet DG. Aquaretic effect of niravoline (RU 51599), a kappa opioid agonist in healthy volunteers. J. Am. Soc. Nephrol. 1994; 5: 373. (Abstract).
14. Hamon G, Fortin M, Le Martret O, Jouquey S, Vincent JC, Bichet DG. Pharmacological profile of niravoline, a new aquaretic compound. J. Am. Soc. Nephrol. 1994; 5: 272 (Abstract).
15. 1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology 1991; 100: 494-501.
16. Lee SS, Girod C, Valla D, Geoffroy P, Lebrec D. Effects of pentobarbital sodium anesthesia on splanchnic hemodynamics of normal and portal-hypertensive rats. Am. J. Physiol. 1985; 249: G528-32.
17. Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: A new experimental model for cirrhosis in the rat. Br. J. Exp. Pathol. 1984; 65: 305-11.
18. Champigneulle B, Braillon A, Kleber G, Gaudin C, Cailmail S, Lebrec D. Adenosine and hemodynamic alterations in cirrhotic rats. Am. J. Physiol. 1991; 260: G543-7.
19. Moreau R, Komeichi H, Kirstetter P et al. Altered control of vascular tone by adenosine triphosphate-sensitive potassium channels in rats with cirrhosis. Gastroenterology 1994; 106: 1016-23.
20. Komeichi H, Moreau R, Cailmail S, Gaudin C, Lebrec D. Blunted natriuresis and abnormal systemic hemodynamic responses to C-type and brain natriuretic peptides in rats with cirrhosis. J. Hepatol. 1995; 22: 319-25.
21. Bosch-Marce M, Jimenez W, Angeli P et al. Aquaretic effect of the κ-opioid agonist RU 51599 in cirrhotic rats with ascites and water retrention. Gastroenterology 1995; 109: 217-223.
22. Hartleb M, Moreau R, Gaudin C, Lebrec D. Lack of pressor hyporesponsiveness to the L-type calcium channel activator, Bay K 8644, in rats with cirrhosis. J. Hepatol. 1995; 22: 202-7.
23. Lee SS, Hadengue A, Moreau R, Girod C, Jiron MI, Lebrec D. Naloxone does not alter hemodynamics in cirrhosis. Studies in humans and rats. J. Hepatol. 1987; 5: 149-53.
24. Bernton EW, Long JB, Holaday JW. Opioids and neuropeptides: Mechanisms in circulatory shock. Fed. Proc. 1985; 44: 290-9.